It's out! Much pleased to have contributed my Honours project @umanitobasci @um_bmg to this groundbreaking discovery describing a non-canonical role for OTX2 in Group 3 medulloblastoma. See attached thread for the story 👇

RT @sapna_pho: Are you a #childhoodCancer survivor? Share your story to help improve #survivorship care in Canada! Take part in an online s….

RT @paulbeavis4: Delighted to share our new approach to enhance CAR T cell function in solid tumours published today @Nature. In this work….

RT @BrainTumourFdn: Meet Camila Muñoz-Gomes, our 2025 Winnipeg Brain Tumour Walk Ambassador! Diagnosed in 2022, Camila found strength throu….

RT @wokesalaryman: The year my son got cancer. DISCLAIMER: THIS IS A PRO BONO PIECE WRITTEN IN COLLABORATION WITH THE CHILDREN'S CANCER FO….

RT @KirstyDuncanPhD: Science and research matter. They are fundamental building blocks of Canada. We need a minister with research in the….

RT @CCMB_Research: We were honoured to host Dr. Sheila Singh, Surgeon-Scientist from @McMasterU, a trailblazer in pediatric brain cancer r….

RT @CCMB_Research: It's Research Day and we’re proud to welcome more than 30 students from @UM_RadyFHS as they present their cancer researc….

RT @hubeythebionerd: Had a great time at BMG Research Day presenting my poster on behalf of the Michaels Lab! Huge thanks to my mentor @pau….

RT @julielajoie13: If you are a Canadian Researcher, faculty member, RA, PDF or graduate student in Canada please consider signing our lett….

RT @CancerCareMB: Catch cancer early — when it’s most treatable. ✔️ BreastCheck (50–74): Mammogram every 2 yrs.✔️ CervixCheck (21–69): Pap….

Thank you @BioCanRx Cancer Stakeholder Alliance for inviting me to participate in this year's Learning Institute! I couldn't think of a better way of celebrating #DaffodilMonth than with my #TeamManitoba @CCMB_Research @CancerCareMBFdn Patient Scholars, Sandra and Cynthia 💛🩷💚

. Meghan Kates' award-winning HQP plenary talk on immuno-metabolism, @LivnatJerby's groundbreaking synbio technologies, and the plenaries ending on a high note with @MiglioriniDenis's novel CAR designs for high-grade gliomas.

My personal favourites from this year's Summit included: @lab_rezvani's scientific keynote on their amazing translational discoveries on CAR-NK cells, Milan Heck's eye-opening patient partner keynote, @Shan_Snelling's wonderful patient-grad student partnership program. .

This plenary was concluded by Dr. Christian Hinrichs @CSHinrichsMD @RutgersCancer who presented their progress in utilizing cell therapies against HPV-related epithelial cancers.

HQP Leanne Palichuk (Lee Lab @UCalgary) talked about her work on utilizing rare DN T cells to improve the potency of anti-tumour T cells against relapsed pediatric AML.

Then, Dr. Marie Bleakley @fredhutch featured their innovative work on TCR T cells against minor histocompatibility antigens for patients who relapse post-HSCT.

First, Dr. Doug Mahoney @Charb_Cancer @UCalgary presented on their Canadian clinical trial using GCAR1 CAR T cells, which target GPNMB on sarcomas.

Sandra (my Patient Scholar) and I were tasked to present on Plenary 1: Clinical Testing of Innovative T cell Therapies for Cancer. This thought- (and hope-) provoking plenary highlighted novel T-cell therapies and their progress towards clinical utility.

This year, we had 5 outstanding plenaries on T cell therapies, non-T players of the immune system, immuno-metabolism, spatial immunobiology, and mRNA-based immunotherapies.

That's a wrap for this year's @BioCanRx #Summit4CI!.Here are some "bites" from Canada's Immunotherapy network from the lens of a Learning Institute Scholar— a thread.